|
Baseline characteristics
|
Overall (n = 55)
|
SVR (n = 28)
|
no SVR (n = 27)
|
p
|
AOR
|
95% CI
|
p
|
|---|
|
Age (years; SD)
|
43; 3.9
|
42; 4.3
|
44; 3.2
|
0.072
|
0.948
|
0.798–1.127
|
0.546
|
|
Sex (male)
|
46 (84%)
|
23 (82%)
|
23 (85%)
|
0.763
| | | |
|
Patients on HAART
|
49 (89%)
|
24 (85%)
|
25 (92%)
|
0.421
| | | |
|
Baseline CD4 cells/μL; SD
|
540; 298
|
536; 228
|
540; 356
|
0.184
| | | |
|
HIV-RNA cp/mL
|
<50
|
<50
|
<50
| | | | |
|
HCV genotype
| | | | | | | |
|
1
|
21 (38%)
|
6 (21%)
|
15 (56%)
|
reference
|
reference
|
reference
|
reference
|
|
not 1
|
34 (62%)
|
22 (79%)
|
12 (44%)
|
0.019
|
5.457
|
1.256–23.721
|
0.024
|
|
HCV viremia (Log IU/mL); SD
|
5.87; 0.7
|
5.67; 0.8
|
5.96; 0.5
|
0.102
| | | |
|
ALT (IU/L); SD
|
100; 60
|
104; 62
|
90; 57
|
0.261
| | | |
|
BMI; SD
|
23.4; 2.2
|
23.6; 2
|
22.8; 3.2
|
0.460
| | | |
|
Hyperglicemia or diabetes
|
19 (34%)
|
4 (14%)
|
15 (55%)
|
0.001
|
0.113
|
0.024–0.528
|
0.006
|
|
Cholesterol >200 mg/dL
|
10 (18%)
|
8 (28%)
|
2 (7%)
|
0.078
|
8.373
|
1.125–62.316
|
0.038
|
|
LDL >100 mg/dL
|
15 (27%)
|
10 (36%)
|
5 (18%)
|
0.062
| | | |
|
Lipoatrophy
|
29 (53%)
|
13 (46%)
|
16 (59%)
|
0.455
| | | |
